These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21214423)

  • 1. Effect of particle size of parenteral suspensions on in vitro muscle damage.
    Brazeau G; Sauberan SL; Gatlin L; Wisniecki P; Shah J
    Pharm Dev Technol; 2011; 16(6):591-8. PubMed ID: 21214423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-in vivo myotoxicity of intramuscular liposomal formulations.
    al-Suwayeh SA; Tebbett IR; Wielbo D; Brazeau GA
    Pharm Res; 1996 Sep; 13(9):1384-8. PubMed ID: 8893279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of PLGA microsphere size effect on myotoxicity using the isolated rodent skeletal muscle model.
    Brazeau GA; Sciame M; al-Suwayeh SA; Fattal E
    Pharm Dev Technol; 1996 Oct; 1(3):279-83. PubMed ID: 9552310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myotoxicity studies of O/W-in situ forming microparticle systems.
    Rungseevijitprapa W; Brazeau GA; Simkins JW; Bodmeier R
    Eur J Pharm Biopharm; 2008 May; 69(1):126-33. PubMed ID: 18036794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the myotoxicity of pharmaceutical buffers using an in vitro muscle model: effect of pH, capacity, tonicity, and buffer type.
    Napaporn J; Thomas M; Svetic KA; Shahrokh Z; Brazeau GA
    Pharm Dev Technol; 2000; 5(1):123-30. PubMed ID: 10669926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of the cytotoxic effect of Bothrops jararacussu venom on mouse extensor digitorum longus and soleus by potassium channel blockers and by Na(+)/K(+)-ATPase inhibition.
    Tomaz MA; Fernandes FF; El-Kik CZ; Moraes RA; Calil-Elias S; Saturnino-Oliveira J; Martinez AM; Ownby CL; Melo PA
    Toxicon; 2008 Sep; 52(4):551-8. PubMed ID: 18675839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular bupivacaine injection dose-dependently increases glutamate release and muscle injury in rats.
    Cherng CH; Wong CS; Wu CT; Yeh CC
    Acta Anaesthesiol Taiwan; 2010 Mar; 48(1):8-14. PubMed ID: 20434107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of nitric oxide in myotoxicity produced by diisopropylphosphorofluoridate (DFP)-induced muscle hyperactivity.
    Gupta RC; Milatovic D; Dettbarn WD
    Arch Toxicol; 2002 Dec; 76(12):715-26. PubMed ID: 12451448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery.
    Brazeau GA; Attia S; Poxon S; Hughes JA
    Pharm Res; 1998 May; 15(5):680-4. PubMed ID: 9619774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro model to evaluate muscle damage following intramuscular injections.
    Brazeau GA; Fung HL
    Pharm Res; 1989 Feb; 6(2):167-70. PubMed ID: 2762216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropivacaine myotoxicity after single intramuscular injection in rats.
    Amaniti E; Drampa F; Kouzi-Koliakos K; Kapoukranidou D; Pourzitaki C; Tsalie E; Vasilakos D
    Eur J Anaesthesiol; 2006 Feb; 23(2):130-5. PubMed ID: 16426467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.
    Kranz H; Brazeau GA; Napaporn J; Martin RL; Millard W; Bodmeier R
    Int J Pharm; 2001 Jan; 212(1):11-8. PubMed ID: 11165816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of creatine supplementation on mass and performance of rat skeletal muscle.
    Young RE; Young JC
    Life Sci; 2007 Aug; 81(9):710-6. PubMed ID: 17707068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notexin causes greater myotoxic damage and slower functional repair in mouse skeletal muscles than bupivacaine.
    Plant DR; Colarossi FE; Lynch GS
    Muscle Nerve; 2006 Nov; 34(5):577-85. PubMed ID: 16881061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats.
    Tonomura Y; Mori Y; Torii M; Uehara T
    Toxicology; 2009 Dec; 266(1-3):48-54. PubMed ID: 19854236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an in vitro model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed solvent systems.
    Brazeau GA; Fung HL
    Pharm Res; 1989 Sep; 6(9):766-71. PubMed ID: 2813273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
    Sigfridsson K; Lundqvist AJ; Strimfors M
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1479-86. PubMed ID: 19929207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).
    Atef E; Belmonte AA
    Eur J Pharm Sci; 2008 Nov; 35(4):257-63. PubMed ID: 18706499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat.
    Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
    Anticancer Res; 2011 Jun; 31(6):2023-8. PubMed ID: 21737618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.